BIO is the world’s largest support association representing biotechnology companies, academic and research institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. Each year, their meetings gather industry executives and representatives to promote scientific and business collaborations.

Umecrine Cognition is currently conducting a Phase 1b/2 clinical trial to evaluate the therapeutic effect of its lead drug candidate, golexanolone, targeting severe fatigue and cognitive impairment in Primary Biliary Cholangitis (PBC). The randomization of patients into the trial’s second part, Part B, a 4-week-treatment study, was recently initiated. During April to June, more than 30 study sites in eight countries will be engaged in the study. The first patients were randomized on May 7 in the UK. Data is expected in H1/2025.

“The development of our lead drug candidate, golexanolone, is currently taking important steps forward. During the beginning of 2024, we have advanced our ongoing clinical Phase 1b/2 trial in primary biliary cholangitis patients with severe fatigue and cognitive impairment to its next stage, following positive comments from our internal safety review committee. The cognitive symptoms associated with PBC are extremely debilitating for these patients, hindering them from living normal active lives. There is a significant unmet medical need among these patients and golexanolone was granted Orphan Drug Designation (ODD) by the US FDA in January 2023. We look forward to focused meetings with potential partners at this year’s BIO in San Diego, with the aim to accelerate our pipeline development,” says Anders Karlsson, CEO of Umecrine Cognition.

For further information, please contact:

Anders Karlsson, CEO, Umecrine Cognition AB
Phone: +46 70 – 918 00 10, e-mail: anders.karlsson@umecrine.se

About Umecrine Cognition AB

Umecrine Cognition AB develops a completely new class of pharmaceuticals against neurological disturbances in the brain that may arise as a consequence of several underlying diseases, leading to strongly reduced cognitive functions and wakefulness. Results from an internationally recognized clinical Phase 2 study indicates that the company’s most advanced drug candidate, golexanolone, normalizes the brain’s signaling and improves cognition as well as wakefulness in patients diagnosed with hepatic encephalopathy. The continued drug development will initially focus on patient groups whose symptoms arise from chronic liver diseases. The mode of action is however relevant in a number of other indications. For more information, visit www.umecrinecognition.com.